4ZB.F Duality Biotherapeutics, Inc.
- Market cap
- EUR 1.09B
- P/E
- -
- P/B
- 5.51x
- ROE
- -106.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4ZB.F undervalued?
Graham numberThe Graham number of Duality Biotherapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Duality Biotherapeutics, Inc. fundamental analysis
No fundamental analysis for Duality Biotherapeutics, Inc. yet.
Duality Biotherapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, eso…
Full company profileDuality Biotherapeutics, Inc. financial statements
Duality Biotherapeutics, Inc. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 1.60M | 1.79B | 1.94B | 1.85B |
| Gross Profit | 1.60M | 1.36B | 785M | 589M |
| Operating Income | -370M | 741M | -203M | -455M |
| EBITDA | -385M | -197M | -1.01B | -2.58B |
| Net Income | -387M | -358M | -1.05B | -2.59B |
| EPS | -4.65 | -4.30 | -13 | -29 |
| Balance Sheet | ||||
| Total Assets | 464M | 1.50B | 2.09B | 3.89B |
| Total Liabilities | 1.23B | 2.62B | 4.11B | 1.47B |
| Shareholders' Equity | -769M | -1.12B | -2.02B | 2.43B |
| Cash & Short-term Investments | 376M | 1.13B | 1.21B | 1.28B |
| Cash Flow | ||||
| Operating Cash Flow | -299M | 816M | 286M | 195M |
| Capital Expenditure | 22.2M | 35.9M | 31.2M | 13.7M |
| Free Cash Flow | -322M | 780M | 255M | 181M |
| Ratios | ||||
| ROE | - | - | - | -106.9% |
| ROA | -83.5% | -23.8% | -50.3% | -66.7% |
| Net Profit Margin | -24,193.1% | -20.0% | -54.1% | -140.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Duality Biotherapeutics, Inc. dividends
Duality Biotherapeutics, Inc. has not paid dividends in the last 4 fiscal years.
Who owns Duality Biotherapeutics, Inc.
- Insiders 19.40%
- Institutions 41.14%
- Public & others 39.46%
- Shares outstanding 91.0M
- Free float 50.9M
Duality Biotherapeutics, Inc. company profile
- Company name
- Duality Biotherapeutics, Inc.
- Ticker
- 4ZB.F
- ISIN
- KYG2929M1087
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 266
- Fiscal year end
- December
- Address
- Full floor, 11th Floor, Shanghai, China, 201204
- Phone
- 86 21 2601 8728
- Website
- dualitybiologics.com
About Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; BeOne to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC; and Genentech, Inc. to develop antibody-drug conjugates. The company was incorporated in 2019 and is headquartered in Shanghai, China.
Duality Biotherapeutics, Inc. management
10- Dr. Zhongyuan Zhu M.B.A., Ph.D.CEO & Chairman · born 1970
- Mr. Shaoren ZhangCFO & Executive Director · born 1986
- Dr. Yang QiuChief Scientific Officer & GM of DualityBio US · born 1973
- Ms. Wen SiExecutive Director of Human Resources · born 1979
- Ms. Jiali YuanHead of Legal & Compliance and Joint Company Secretary · born 1987
- Dr. Hua Mu M.D., Ph.D.Global Chief Medical Officer · born 1963
- Mr. Xin Wang C.F.A.Chief Business Officer · born 1972
- Dr. Haiqing Hua Ph.D.Senior VP, Head of Drug Discovery & Executive Director · born 1980
- Mr. Xin YuVP & Head of Regulatory Affairs · born 1982
- Mr. Chi Kit LeungJoint Company Secretary